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A novel human retrovirus, human T  cell leukemia virus (HTLV) 1 has recently been 
isolated  from a  variety of adult  T  cell  leukemias  and  lymphomas  that  have so  far 
generally exhibited a particular geographic distribution in the southern United States, 
West  Indies,  and  Southern  Japan  (1-3;  M.  Popovic,  manuscript  in  preparation). 
Specific antibodies  to HTLV  proteins  have been  found in  virus-positive cases  (4-9) 
often in family members  (9)  and much less frequently in the general population.  To 
further  study  the  incidence  of HTLV  in  large  patient  populations,  a  monoclonal 
antibody to the HTLV structural protein, p 19 (V. S. Kalyanaraman and R. C. Gallo, 
manuscript in preparation),  has been used to examine T  cells of patients and normal 
donors for evidence of HTLV  expression  (10). 
The monoclonal antiTp 19 immunoprecipitates a  19,000-dalton structural protein of 
HTLV. The antigen  is located at  the surface of fixed  HTLV-infected T  cells and is 
not detected in HTLV-  malignant or normal T  ceils of any type (10). During a recent 
screen  of anti-pl9  reactivity  with  a  large  number  of normal  human  tissues,  we 
observed  that  anti-pl9  reacted  strongly  with  the  epithelial  component  of normal 
human  thymus.  Thus,  in  this  study,  we  characterized  the  specificity  of anti-pl9 
binding to human thymus, and sought other HTLV antigens in normal thymic tissue. 
We  demonstrated  the  extent  of reactivity  of anti-pl9  with  thymic epithelium  as  a 
function of the age of the donor of the thymus and showed that all anti-p 19 + thymic 
epithelial  cells  contain  thymosin  c~1  and  thymopoietin.  Moreover,  no'other  HTLV 
proteins or proviral HTLV  DNA were demonstrated in anti-p 19 + thymic epithelium. 
Thus,  in normal  human  thymus,  the antigen  defined  by anti-pl9  is specific for the 
neuroendocrine  component  of thymic  epithelium  and  is  acquired  during  normal 
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thymic epithelial ontogeny. Our results clearly indicate that  thymic epithelium is not 
generally  infected  with  HTLV.  Two  other  possibilities  are  discussed:  (a)  that  the 
observations simply reflect a cross-reactivity between the HTLV  and thymic epithelial 
antigens;  and  (b)  that  HTLV  p19  is a  host-encoded  protein  selectively expressed  in 
normal thymus and also induced in HTLV-infected  T  cells and incorporated  into the 
virus. 
Materials  and  Methods 
Monoclonal Antisera.  Hybridoma  12/1-2,  a  cloned  murine  hybridoma  line,  produced  the 
IgG1 monoclonal anti-HTLV p19 (10).  The immunizing antigen was prepared as follows: cells 
producing HTLV were grown in RPMI  1640 medium containing 20% fetal calf serum. HTLV 
was concentrated  from cell culture supernatants  by continuou.~  flow centrifugation through  a 
sucrose gradient. The virus pool was subsequently centrifuged through 30% glycerol in a buffer 
composed of 0.01  M  Tris-HCI, pH 8.0, 0.1  M  EDTA (TNE) onto a  100% glycerol cushion, and 
rebanded  on a  20-60%  sucrose  gradient  in TNE. The  virus was  pooled based  on  its reverse 
transcriptase  activity with poly(A)n dTla as template  (1)  and  its density. The latter peaked  at 
~1.17  g/ml. HTLV was disrupted  by adding an equal volume of disruption buffer composed 
of 100 mM Tris-HC1, pH 7.9, 0.5% Triton X-100, 0.04 M  dithiothreitol (DTT), 2 mM EDTA, 
1 M  KCI, and 2 mM phenylmethylsulfonyl fluoride (PMSF)  and stirring for I  h at 4°C. After 
centrifugation at  15,000  rpm for 30 min, the supernatant  solution was used for immunizations. 
Monoclonal A2B5 binds to a  GQ ganglioside antigen on all neuroendocrine vertebrate tissues 
(11), and in human thymus selectively binds to the entire neuroendocrine component of thymic 
epithelium (12). 2 
PolyclonalAntisera.  Rabbit anti-thymosin al (the generous gift of Dr. Allen Goldstein, George 
Washington  University, Washington,  DC)  and  anti-thymopoietin  (the  generous  gift  of Dr. 
Gideon Goldstein, Ortho Pharmaceutical,  Raritan, N J) were used as previously described (12). 
Goat anti-HTLV p24 was prepared  against  the homogeneously purified core protein  (13).  Its 
titer  in  a  radioimmunoprecipitation  (RIP)  assay  was  1:180,000  for  20%  precipitation  of the 
labeled  antigen.  It  was  used  in  indirect  immunofluorescence  at  a  1:100  dilution,  with  an 
affinity-pure  fluorescein-conjugated  rabbit  anti-goat  IgG  (H  and  L  specific)  (Tago,  Inc., 
Burlingame,  CA).  Antibody  to  HTLV  was  raised  in  a  goat  using  detergent-ether  disrupted 
virus.  In  RIP  assays,  its  titer  far  20%  precipitation  of Iabeled  HTLV  p19  was  i:2,000.  In 
immunofluorescence assays it was used at a  1:1,000 dilution with an affinity-purified fluorescein- 
conjugated rabbit  anti-goat IgG. 
Acquisitwn  and Preparatwn of Tissue.  Normal fetal thymus  tissue was obtained at the time of 
therapeutic  abortion.  In one case tissue was obtained  from a  24-wk  fetal product  of a  septic 
abortion. Normal thymic tissue from neonates or older subjects was obtained during corrective 
cardiovascular  surgery.  Myasthenia  gravis  (MG)  thymic  tissue  was  obtained  at  the  time  of 
therapeutic  thymectomy.  Fetal liver and  spleen and  adult  skin,  lymph node, spleen, adrenal, 
thyroid, prostate, stomach, kidney, uterus, parotid, breast, liver, colon, and brain were obtained 
at  autopsy  no  later  than  4  h  after  death.  Pancreas  and  adrenal  tissue  were  obtained  from 
specimens taken  during abdominal  surgical  procedures.  3 x  3-mm  portions of all tissue types 
were snap  frozen in an ethanol-dry  ice slurry, and stored in liquid N2 until used. Suspensions 
of thymocytes, normal peripheral  blood cells, tissue tumor cells, or peripheral  blood leukemic 
cells were prepared as described previously (14,  15). 
Indirect  Irnmunofluorescence Assay for Monoclonal Anti-pl9  or A2B5 Reactivity.  All frozen  tissue 
was embedded in OCT compound (Scientific Products, McGraw Park, IL), 4-/*m frozen sections 
were cut, and the sections were fixed for 5 min in cold acetone and stored at -100°C. Acetone- 
fixed tissue slides were incubated  for 30 min in a  moist chamber with a  saturating amount of 
monoclonal antibody  (1 : 1,000  of anti-p 19 ascites,  1:500 of A2B5 ascites, and  1  : 1,000  or  1:500 
of P3  X  63/Ag8 control ascites).  After three rinses in cold phosphate-buffered  saline  (PBS), a 
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saturating amount (1:100 final dilution) of affinity-pure fluorescein isothiocyanate-conjugated 
(fluorescein/protein 6.0)  goat  anti-mouse IgG  (Tago,  Inc.)  was  layered  on  the  slide  and 
incubated 30 min. After one rinse in PBS, the slides  were briefly dipped in distilled water, 
allowed to air dry, overlayed with 30% glycerol in PBS,  coverslipped, and read on a  Nikon 
Optiphot microscope (Garden City, NY)  (15). Double indirect immunofluorescence  with anti- 
thymic hormone antisera and  monoclonal antibodies A2B5  or  anti-pl9 was  performed  as 
described in detail (12). 
Immunoperoxidase-Peroxidase Assay for  Anti-pl9 Reactivity.  After  preincubation of the  tissue 
sections with 10% nonimmune  goat serum, slides were incubated for 60 rain at room temperature 
with 1:1,000 diluted anti-p19 or P3 ascitic fluid. A second 45-min incubation was performed 
with a  1:50 dilution of horseradish peroxidase-conjugated goat anti-mouse IgG (N. L. Cappel 
Laboratories, Inc., Cochranville, PA). Slides were developed by incubation for  15 min with a 
solution of diaminobenzidine (0.5 mg/ml) and hydrogen peroxide  (0.001%) in 0.05  M  Tris 
buffer at pH 7.6 and were eounterstained with hematoxylin (16). 
Assay for Tetanus Toxin (TT) Binding to Thymus.  TT binds to GD and GT gangliosides which, 
in the thymus, identify all A2B5 + neuroendocrine thymic epithelial cells (12). Human thymus 
sections were also incubated with purified TI"  (kindly supplied by R.  O.  Thomson of the 
Wellcome Research Laboratories, Beckenham, England), 0.1 Izg/ml diluted in PBS 1% albumin 
for 30 min at room temperature, washed three times in PBS, incubated with 1:100 dilution of 
monoclonal anti-TT antibodies 3DB and 3B3 (kindly supplied by V. R. Zurawski of Centocor, 
Inc. Malvern, PA), washed three times, and then incubated as described above for antibody 
A2B5 with fluorescein-conjugated anti-mouse IgG (12).  2 
Indirect Immunofluorescent Assay for Surface Binding of Anti-p l9 and Antibody A2B5 to Viable Thymic 
Epithelial  Cells.  The thymocytes from fresh normal or MG thymus tissue were gently teased 
from thymic epithelium with forceps using mechanical dissociation, and the resulting thymo- 
cyte-free thymic epithelium was cut into 1 X l-mm pieces and stained in suspension with either 
P3  ×  63/Ag8  ascites  as  control  (1:1,000  or  1:500),  anti-pl9 (I:1,000), or  A2B5  (1:500)  as 
previously described for cells in suspension (14). After staining with fluorescein-conjugated  goat 
anti-mouse IgG, the tissue pieces were overlayed in 30% glycerol in PBS with a coverslip and 
viewed by fluorescent microscopy. Cell surface reactivity of p 19 with a variety of lymphoid cells 
in suspension was determined by indirect immunofluoreseence  and cytofluorography using the 
Ortho 50H cytofluorograph (Ortho Instruments, Westwood, MA) as described (14). 
Blocking of Anti-p t9 Antibody Binding to Thymus Epithelium with Extracts of Thymic Epithelium or 
HTLV.  500 mg of purified MG thymic stroma (shown by indirect immunofluorescence  to be 
strongly anti-p  19  +) was homogenized in a Dounce homogenizer with 2.0 ml of extraction buffer 
containing 1% NP40, 2 mM PMSF, 10 mM iodoacetamide in 10 mM Tris-HCl buffer, pH 8.0. 
After homogenization, the extract was centrifuged at 27,000  rpm for 60 min, and the super- 
natant was collected. As controls, sheep erythrocyte (SRBC) membranes (previously shown to 
be anti-pl9-), 24-wk fetal thymus (shown to be 99% p19-), and adult spleen (also p19-), were 
similarly extracted and used at concentrations from  1.5 to 3.6/lg/ml. Disrupted HTLV was 
prepared and solubilized as previously described (13). HTLV p 19 was also purified as previously 
described (13). Briefly, detergent disrupted HTLV was freed of nucleic acids by passage through 
DEAE-cellulose. The unadsorbed protein fraction was dialyzed against buffer A (50 mM Tris- 
HCI, pH 7.9, 1 mM DTT, 20% glycerol,  and 0.1 mM PMSF) and passed through a column of 
phosphocellulose equilibrated with the same buffer. The column was successively washed with 
0.7 and  1.2 M  NaCI in buffer A. The  1.2 M  NaCI wash contained nearly pure HTLV p19, 
which was  further purified by high-pressure liquid chromatography  (HPLC)  using a  C-18 
column. The column was developed with a gradient of acetonitrile in 0.1% trifluoroacetic acid. 
HTLV p19 was eluted between acetonitrile concentrations of 60-75% and was lyophilized and 
reconstituted in 50 mM phosphate buffer, pH 7.5, before use. For blocking, 10/~1 of either adult 
thymie epithelium (180/~g), fetal thymic epithelium (360/~g), adult spleen (360 ~g), SRBC (75 
/~g) extract,  10/~1 of purified HTLV p19 (2.75/~g),  20/zl of disrupted HTLV (37/~g), or 10/zl 
of extraction buffer were added to a subsaturating amount (1:25,000) of monoclonal anti-pl9. 
The mixture was allowed to stand 15 rain and was then added to 4-/zm sections of thymus as 
described above. Inhibition of anti-pl9 binding by the various extracts or buffer control was 
determined by lack of fluorescence of thymic epithelium. 910  HUMAN THYMIC  EPITttELIAL  ANTIGEN 
Radioimmunoassay for  Binding of Purified HTLV p19  to  Monoclonal Anti-pig.  A  solid-phase 
radioimmunoassay  was carried out as previously described (17). Briefly, ascites fluid containing 
monoclonal anti-p  19 (12/1-2)  was diluted 1:1,000 in PBS/Tween and duplicate 50-#1 aliquots 
were incubated in purified HTLV pl9-coated microtiter wells for 45 rain at 37°C. Unbound 
proteins were aspirated, and the plate was washed three times with PBS/Tween. An appropriate 
dilution of rabbit anti-mouse IgG in PBS/Tween was added to each well. After incubation and 
washing as above, iodinated protein A (50,000 cpm/50/A PBS/Tween) was added to each well. 
Wells were subsequently incubated, washed, and counted in a gamma counter. 
DNA  Blotting of Thymus and  Thymus Epithelial DATA with Cloned HTL V Probes.  Sequences 
derived from the 5' and 3' termini of HTLV (450 and 500 nucteotides, respectively)  have been 
molecularly cloned in pBR322 (V. Manzari and R. C. Gallo, unpublished results). These were 
labeled with a2p by nick translation (18) and used as probes.  High molecular weight DNA from 
thymus, thymic epithelium, normal thymocytes, and two HTLV-positive cell lines was digested 
with  the  restriction endonuclease Kpn  I  and  blot  hybridized to  labeled  HTLV  probe  as 
described (19). 
Results 
Reactivity of Anti-pl9 with  Thymic Epithelium.  As previously reported  (10), anti-p19 
did  not  react  with  antigens of normal  thymocytes.  However,  when  anti-pl9 was 
assayed for reactivity on frozen thymus 4-#m tissue sections from a  30-too-old normal 
child, the entire subcapsular cortex and medullary thymic epithelium (as defined by 
A2B5 and TT reactivity [12] 2)  was anti-pl9  +  (Fig.  1A and B). However, in contrast 
to A2B5 or TT reactivity, anti-pl9 reactivity was variable from thymus to thymus in 
the amount of thymic epithelium labeled. Ontogenic study of normal thymic tissue 
from  t3  wk  fetal  gestation  through  60  yr  of age  (Table  I)  demonstrated  that  the 
reactive antigen was  acquired during thymic ontogeny. Whereas  the  entire thymic 
epithelium component of all fetal and adult  thymuses tested were A2B5 +,  no anti- 
Fro.  1.  Monoclonal  anti-pl9 reacts with thymic epithelium of normal thymus. (A) Light micro- 
graph of hematoxylin and eosin-stained fl'ozen  section of thymic medulla. Structure labeled tt is a 
Hassall's corpuscle. A loci of medullary lymphoid cells is labeled L. (B) Fluorescent micrograph of 
the same field showing the anti-pl9 reactive epithelial cells (arrows) around anli-pl9- lymphoid 
cells {L) (X 400). HAYNES ET AL.  911 
TAnLn  I 
Reactivity of Anti-p l9 Monoclonal Antibody with Normal Thymus Tissue as Determined  by Indirect 
Immunofluorescence 
Thymus  Age  Pattern of reactivity of 
number  anti-p 19 antibody 
1  8 wk gestation 
2  15 wk gestation 
3  24 wk gestation 
4  4 mo (postnatal) 
5, 6  12 mo 
7  30 mo 
8  60 yr 
All areas of thymic epithelium were nonreactive. 
Most cortical and medullary areas were nonreactive. Occa- 
sional linear arrays of p19  + dendritic cells were located in 
the subcapsular cortical region of rare thymic tobules. 
Most cortical and medullary areas were nonreactive. Occa- 
sional linear arrays of p 19  + dendritic cells were located in 
the subcapsular cortical region of rare thymic lobules. 
All subcapsular cortical areas of each lobule rimmed by 
linear arrays of p 19  ÷ dendritic ceils. Occasional p 19  + cells 
were scattered about upper cortex. Most medullary areas 
contained no p19  + cells. 
All subcapsular cortical areas of each lobule were rimmed 
by linear arrays of p19  + dendritic cells. Occasional p19  + 
cells were scattered about upper cortex. Only occasional 
to few medullary areas contained p 19  + ceils. 
All subcapsular cortical areas of each lobule were rimmed 
by linear arrays of p19  + dendritic cells. Occasional p19  + 
cells were scattered about upper cortex. Most medullary 
areas contained many p19  + cells, 
Streaks of p19  + epithelium were present throughout thymic 
fibrofatty stromal remnant. 
p19  + epithelium was  present  until  15  wk  gestation, and these  anti-p19  + cells were 
limited to only a  few areas of the subcapsular cortex  (Fig. 2A and B). By birth, the 
entire subcapsular cortical thymic epithelial region was anti-p  19 +, whereas the A2B5  + 
medullary component of thymic epithelium was anti-p19- (Fig.  2C).  By 30 rno of 
age, the entire A2B5  + neuroendocrine component of thymic epithelium was anti-p 19  + 
(Fig.  2D,  E).  In  15  normal thymuses tested  (ages ranging from birth to 68 yr), the 
pattern of anti-p  19 reactivity listed in Table I held true. In addition, in thymic tissue 
from  six  MG patients  (ages  of donors ranging from  7  to  68  yr),  the  entire A2B5  + 
neuroendocrine thymic epithelium was  anti-pl9  +.  Assay  for  anti-pl9 reactivity on 
rabbit or mouse thymic epithelium was negative. Specificity of anti-p19 was demon- 
strated by blocking of a  nonsaturating amount of anti-p19 (1:25,000)  by anti-p 19  + 
thymic epithelium membrane extracts, but not by anti-pl9- SRBC fetal thymus or 
adult spleen membrane extracts (Table II). 
Extracts  of  whole  HTLV  and  high  pressure  liquid  chromatography  (HPLC)- 
purified HTLV  p19 antigen were incubated with subsaturating amounts of mono- 
clonal  anti-pl9  (1:25,000-1:50,000)  before  incubation with  thymic  tissue  sections. 
Both HTLV whole extract and purified HTLV p19 antigen completely inhibited the 
binding of anti-p19  to  thymic  epithelium  (Table  II).  To  show  directly  that  the 
monoclonal  anti-p19  bound  HPLC-purified  HTLV  p19,  binding of  anti-p19  to 
varying amounts of plate bound purified p19  antigen in a  solid phase radioimmu- 
noassay was performed. The results are shown in Fig. 3. 
A goat antiserum to disrupted HTLV reacted in indirect immunofluorescence  assay 
to normal neuroendocrine thymic epithelium in a pattern similar to monoclonal anti- 912  HUMAN TItYMIC  EPITItELIAL ANTIGEN 
Fro. 2.  Reactivity of anti-pl9 antibody  to thymic epi- 
thelium  is acquired cortex (SCC) and cortex (C) of 15- 
wk  fetal  thymus  stained  with  anti-pl9  during 
ontogeny.  (A) Fluorescent-negative micrograph of sub- 
capsular  showing no  anti-p19  + cells. Thymic  medulla 
was anti-pl9- as well (not shown). (B)  Fluorescent mi- 
crograph of 15-wk fetal thymus showing localized area of 
p19  + cells in  subcapsular  cortex (arrows). All adjacent 
cortex and medulla areas were anti-p 19 nonreactive. (C) 
Fluorescent  micrograph  of 4-too-old newborn  thymus 
showing  entire  subcapsular  cortex  (arrow)  anti-pl9  +, 
while  thymus  capsule, cortex  (C), and  medulla  (not 
shown) were all anti-pl9-. Note subcapsular cortical anti- 
p19  + epithelial cells are more dendritic than those of the 
fetal thymus. 
19  (not  shown).  In  addition,  this antibody  also precipitated soluble purified HTLV 
p19  in  RIP  assays  (not  shown).  Thus,  the  monoclonal  anti-pl9  and  the  polyclonal 
goat  anti-HTLV  antibody  bound  to  both  normal  thymic  epithelium  and  purified 
HTLV  p19 antigen. 
Lack of Reactivity of Anti-p l9 with Other Human Tissues.  Because TT and A2B5 bind 
to all neuroendocrine tissues, a broad screen of anti-p 19 reactivity with many types of 
hematopoietic and  neuroendocrine tissues was performed  (Table III). In contrast  to 
TT  and  A2B5,  anti-p19  did  not  react  with  any  normal  neuroendocrine  or  other 
human tissues tested other than thymic epithelium, However, the basal layer of tonsil, 
adenoid, and esophagus squamous epithelium did react with anti-pI9. HAYNES  ET  AL.  913 
Fro.  2.  (D and E) Fluorescent micrograph of 30-too thymus showing (D) entire subcapsular cortex 
epithelium of two adjacent thymic lobules (arrows) anti-pl9  + and (E) entire medullary epithelium 
anti-p19  + (arrows). H  denotes Hassall's corpuscles (× 400). 
TABLE  II 







Anti-p 19 (1:50,000)  Positive 
Anti-pl9 (1:50,000)  +  2.75 #g purified HTLV p19 antigen  Negative 
Anti-p 19 (1:50,000)  +  36/Lg solubilized whole HTLV extract  Negative 
in 0.5% Triton X 
Anti-p 19 (1:50,000)  +  0.5% Triton X  control  Positive 
Anti-pl9  (1:25,000)  +  180  /lg  Thymic  epithelial  stromal  Negative 
extract in  1% NP-40 
Anti-pl9  (1:25,000)  +  75 #g  SRBC  stromal  extract  in  1%  Positive 
NP-40§ 
Anti-pl9 (1:25,000)  +  360 p.g 24-wk fetal thymus extract in  Positive 
1% NP-40 
Anti-pl9 (1:25,000)  +  360/tg adult spleen extract in  1% NP-  Positive 
40 
Anti-pl9 (1:25,000)  +  1% NP-40 control  Positive 
* P3  X  63/Ag8  ascitic fluid at  1:25,000  or  1:50,000  dilution, either alone or 
with each of the tissue extracts, purified HTLV-associated p19 antigen, or 
controls,  gave  no  fluorescent  staining  pattern  of any  portion  of normal 
human thymus. Blocking experiments were performed as outlined in Mate- 
rials and Methods. 
:~ As determined by indirect immunofluorescence. 
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Fla.  3.  MonocJonal anti-pl9 antibody binds purified HTLV p19 antigen. Varying amounts of 
purified ttTLV p19  (275/~g/ml)  were bound to plastic microtiter wells and assayed for reactivity 
with anti-pl9 as described in Materials and Methods. 
TABLE  III 
Localization  of Anti-p l9 Reactivity  on Normal Tissue or Normal or Malignant 
Hematopoietic  Cells * 
Surface p i 9  Cytoplasmic 
anti-pl9 
Cell type  reactivity  reactivity:~ 
HUT 102 (HTLV+ CTCL line)  -  + 
HTLV+ ATL cultured PBL  -  + 
HUT 78 HTLV-  CTCL§ line  -  - 
HSB-2 T  ALL cell line  -  - 
Fresh normal PBLlJ  -  - 
Fresh thymocytes  -  - 
Fresh thymocytes  -  - 
Fresh AML PBL  -  - 
Fresh hairy cell PBL  -  - 
Fresh T  cell CLL  -  - 
Fresh CTCL leukemia  -  - 
* The  following tissues  (number  tested)  did  not  bind  anti-pl9  monoclonal 
antibody as determined by indirect immunofluorescence or immunoperoxi- 
dase staining techniques on 4-/~m frozen tissue sections: fetal spleen (1), fetal 
liver  (1),  adult  lymph node  (4),  spleen  (l),  liver  (1),  skin  (6),  adrenal  (2), 
pancreas (1), thyroid (1), brain (2), colon (1), breast (l), prostate (1), stomach 
(1), kidney (l), parotid (1), and uterus (1). 
~t Fresh leukemia cells cultured 7 d in T  cell growth factor supplemented with 
RPMI  1640 +  20% fetal calf serum medium. 
§ Cutaneous T  cell lymphoma. 
II Peripheral blood leukocyte. 
Characterization  of Surface  vs.  Intracytoplasmic  Reactivity  of Anti-p19.  Because  HTLV 
p19  is not exposed  on the surface of HTLV-infected  malignant  T  cells, but  can  only 
be  visualized  in  fluorescent  assays  using  fixed  cells  (10),  reactivity  of anti-pl9  was 
tested  on  one  normal  and  two  MG  subjects'  fresh  viable  purified  thymic  epithelial 
cells  in  suspension.  We  found  both  anti-pl9  and  antibody  A2B5  reacted  with  a  cell 
surface rim  pattern  on viable thymic  epithelial  cells  (not shown). 
Next,  a  comparison  was  made  of anti-pl9  reactivity  on  both  fixed and  living cells 
of various  types  including  normal  and  malignant  HTLV  ÷  or  HTLV-  cells  (Table 
III).  While  fixed cultured  PB cells from  a  patient  with Japanese  HTLV  ÷  adult  T  cell 
leukemia  and  the  cutaneous  T  cell  lymphoma  HTLV  ÷  HUT  102  cell  line  reacted 
with  anti-pl9,  surface  reactivity  for  these  anti-pl9 +  living  cells  with  anti-pl9  by 
cytofluorography  was  absent.  As a  control,  a  series of other  types of malignant  cells HAYNES  ET  AL.  915 
were anti-p 19 non-reactive by fluorescent assays on both fixed and living cells (Table 
Ill). 
All  Anti-pl9  Reactive  Thymic  Epithelial  Cells  Contain Thymopoietin  and  Thymosin  al. 
Anti-p 19 reacted with both subcapsular cortical and medullary thymic epithelium in 
all thymic tissue from donors over the age of 30 too. Since this reactivity pattern was 
identical to the pattern seen with A2B5 and TT, and since all A2B5 ÷ and TT + thymic 
epithelial cells contain  thymopoietin  and  thymosin  O~1  (12),  we  wanted  to  confirm 
that  all anti-pl9  ÷  epithelial cells as well contained  thymopoietin and  thymosin ~. 
Using  double  indirect  immunofluorescence  with  rabbit  anti-thymosin  al  or  anti- 
thymopoietin developed with rhodamine-conjugated goat anti-rabbit IgG and  mon- 
oclonal  anti-pl9  developed  with  fluorescein-conjugated  goat  anti-mouse  IgG,  we 
demonstrated  that  all anti-pl9  +  thymic  epithelial cells contained  these  two  thymo- 
trophic hormones  (Fig. 4 A  and B). 
Because all anti-pl9  +  thymic epithelial cells contained  thymosin cq, using double 
immunofluorescence we  next  determined whether  anti-pl9  +  malignant  T  cells con- 
tained  thymosin  c~1. We  found  that  both  the  HTLV +,  HUT  102  cell  line and  the 
HTLV-,  HUT  78  cell  lined  contained  thymosin  c~1, whereas  only  the  HUT  102 
HTLV + cell line was  anti-pl9  +  (data not  shown).  Thus,  although  malignant  HUT 
102 T  cells do produce thymosin c~a, there was no direct correlation between anti-p 19 
reactivity and the presence of thymosin i[1~1 in malignant T  cells. 
Reactivity of  Anti-p l 9 in Abnormal Thymic  Tissue.  Since anti-p 19 reactivity is acquired 
during thymic ontogeny,  we  looked to  see if the  antigen  recognized was present  in 
abnormal  thymic  tissue  from  patients with  thymic  dysplasia (severe combined  im- 
Fie,  4.  All anti-pl9  + thymic epithelial cells contain  thymosin  al.  (A)  30  too-old  thymus  was 
incubated  with anti-pl9 antibody followed by fluoresceinated goat anti-mouse IgG and viewed for 
green  fluorescein excitation.  Arrow  shows anti-pl9  + epithelial  cells. (B)  Same  field  as  in  (A). 
Counter-stained  with rabbit anti-thymosin  al and rhodaminated-goat anti-rabbit IgG and viewed 
for red rhodamine excitation.  Arrow shows thymosin  cq + epithelial cells. Identical results were 
obtained using anti-thymopoietin  instead ofanti-thymosin al (not shown) (× 400). 916  HUMAN THYMIC EPITHELIAL ANTIGEN 
TABLE IV 
Reactivity of Anti-p l 9 in Abnormal Thymic Tissue* 
Th,,  i__zm.c tissue  A2B5  TT  p 19 
source 
SCID~:  +  -  + 
SCID  +  -  - 
Nezelof's syndrome  -  +  - 
Thymoma  +  ND§  - 
Thymoma  +  ND  + 
T ALL[I  +  ND  + 
* As determined by indirect immunofluorescence assay. 
~c Severe combined immunodeficiency disease. 
§ Not done. 
II Thymus autopsy tissue was from a T ALL patient whose leukemic PB cells 
in culture with T cell growth factor-supplemented media were HTLV p19 
and HTLV p24-. 
munodeficiency  disease  and  Nezelof's  syndrome)  2  thymic  epithelial  malignancies 
(thymoma), and thymus lymphoid malignancy (HTLV- T  cell acute lymphoblastoid 
leukemia  [T ALL]). As expected, we found both reactive and nonreactive dysplastic 
and malignant  thymic epithelial  tissues  (Table IV). 
Assay for  the  Presence  of HTL V  Proteins  or  HTL V  DNA  in  Normal  or  MG  Thymic 
Epithelium.  Because  p19  is  an  HTLV  structural  protein,  the  question  arose  as  to 
whether  normal  thymic  epithelium  was  infected  with,  and  thus  a  revervoir  for, 
HTLV.  To  study  this  question,  a  goat  anti-p24  antiserum  that  reacts  with  a  cyto- 
plasmic antigen in HTLV-infected T  cells and immunoprecipitates  the 24,000-dalton 
HTLV  internal  core protein  (14)  was used.  It did not react by indirect  immunofluo- 
rescence with any thymic tissue previously shown to have strongly anti-pl9 + thymus 
epithelium.  Finally, DNA from normal and MG-purified  thymic epithelium,  normal 
whole thymus, normal  thymocytes, and DNA from an HTLV-infected cell line were 
extracted, digested with Kpnl, and probed via hybridization with the 5' (450 IN-) and 
3'  (500  N)  sequence  of HTLV  (V.  Manzari  and  R.  C.  Gallo,  unpublished  results). 
DNA from the cell line infected with  HTLV  showed distinct  bands of hybridization 
with  the HTLV  probes,  whereas  the normal  thymic epithelium,  whole thymus, and 
thymocyte DNA did not  (not shown). 
Discussion 
In this study, we show that monoclonal antibody  12/1-2  (anti-p19)  binds not only 
to HTLV  p19,  which  is expressed  in  HTLV-infected T  cells,  but  to normal  human 
thymic epithelium.  Furthermore,  the  thymic epithelial-reactive  antigen  is  acquired 
during thymic ontogeny. Specificity studies demonstrated  that binding of the mono- 
clonal anti-p 19 to thymic epithelium was completely inhibited  by thymic epithelium 
extracts, whole HTLV extracts, and purified HTLV p 19 antigen (Table II). Moreover, 
a  goat anti-HTLV anti-serum bound to normal thymic epithelium. 
These  observations  gave  rise  to  several  hypotheses  regarding  the  nature  of the 
reactive antigen on thymic epithelium.  (a) Thymic epithelium may be infected during 
ontogeny with HTLV. The observations that anti-pl9 + thymic epithelium  is HTLV 
p24 negative,  that  no HTLV  proviral  DNA sequences can be detected  with  HTLV 
c-DNA probes by Southern blot hybridization techniques, and that all thymus tissues HAYNES ET AL.  917 
tested from donors older than 8 wk gestation were anti-pl9 + provide strong evidence 
against this. Moreover, epidemiologic data strongly suggest that HTLV-associated T- 
cell  leukemia  is  horizontally  passed  as  an  infectious  disease  and  not  by  vertical 
transmission (4-9). Molecular hybridization studies have verified this and proven that 
the infection is postzygotic (3, 21). The observation that all normal, myasthenic, and 
T  ALL  thymuses  tested  were  anti-pl9  +  also  mitigates  against  p19  expression  on 
thymic epithelium  reflecting HTLV infection.  (b)  Anti-pl9  recognizes a  structural 
protein of HTLV and also may bind to a "cross-reactive," host-derived, and therefore 
non-HTLV-associated antigen on thymic epithelium. This possibility is suggested by 
the specificity data (Table II) and by the lack of both HTLV proviral sequences and 
HTLV p24  antigen  in  anti-pl9  + thymic epithelium.  (c)  Monoclonal anti-pl9  may 
recognize a  19,000-dalton host-encoded protein that is induced by HTLV infection of 
cells, contaminates HTLV preparations, and co-purifies with virally encoded HTLV 
p19.  Studies are underway to characterize the reactive thymic epithelial antigen.  If 
this antigen has a  mass of 19,000 daltons, this possibility must  be considered more 
carefully. (d) Finally, HTLV p 19, although a viral structural protein, may be encoded 
by the host rather than the virus. Thus, monoclonal anti-pl9 would specifically react 
not only with HTLV p19 but  also with a  host protein induced to be expressed by 
HTLV  infection  in  malignant  T  cells  that  is  also  normally  expressed  on  thymic 
epithelium. This host protein would be incorporated into the HTLV virion structure 
during viral morphogenesis. Precedents for such a phenomena have been observed in 
adenovirus-transformed mouse cells where a  host  protein  (p53)  becomes associated 
with a 58,000-dalton product of the adenovirus Elb region (21). This p53 host protein 
also binds to SV-40 T  antigen in SV-40 transformed cells (21-23).  In animals with 
SV-40-induced tumors and Abelson leukemia virus-induced leukemia, anti-p53 serum 
antibodies are present (21-23). This latter observation is particularly interesting as it 
has been clearly documented that HTLV-infected patients with Japanese and United 
States adult T  cell leukemia make anti-pl9 antibodies that compete with monoclonal 
anti-pl9 for binding to HTLV (17), Natural antibodies to HTLV p19 have also been 
3  demonstrated by RIP assays. 
While reaction of anti-pl9 has not been detected with any other normal epithelial 
or neuroendocrine tissues (Table III), we have observed binding of monoclonal anti- 
p 19 to prostate adenocareinoma cells, though not to normal prostate tissue. Moreover, 
HPLC-purified HTLV p19 blocked the binding of monoclonal anti-pl9 to prostate 
carcinoma-associated p 19 antigen in a manner similar to blocking anti-p 19 reactivity 
with thymic epithelium (R. S.  Metzgar, R. C. Gallo, and B. F. Haynes, manuscript 
in preparation). This observation again suggests either a host origin for the monoclonal 
anti-pl9 antigen or a cross-reactive phenomenon, and as well suggests other epithelial 
tumors will be found to express this antigen. 
Thus, the data clearly indicate that the normal thymic epithelial anti-pl9 reactive 
antigen is of host origin. At present we cannot resolve the issue whether p19 carried 
by HTLV and found in HTLV-infected cells is of viral or host origin. However, its 
presence  in  thymic epithelium  surface  membranes  and  acquisition  during  thymic 
ontogeny is of considerable interest. It is well recognized (24) that thymic epithelium 
is  critical  to  the  normal  induction  of cell  maturation.  Recently  (25),  it  has  been 
suggested  that  thymic  epithelium  of AKR  mice  induces  amplified  expression  of 
3  Schuepbach  J., and R. C. Gallo. Manuscript submitted for publication. 918  ttUMAN TttYMIC  EPITttELIAI, ANTIGEN 
murine retrovirus genes by thymocytes and induces preleukemic phenotypic changes 
in thymocytes. In humans, Borzy et al.  (26) reported the induction of fatal lymphoma 
after transplantation of cultured thymic epithelium in children with severe combined 
immunodeficiency disease.  Taken  together,  these data suggest that  the study of an 
antigen either shared by cross-reactivity between  HTLV and thymic epithelium,  or 
induced  in  host  T  cells  by HTLV and co-expressed on  normal  thymic epithelium, 
may  well  provide  important  information  regarding  normal  and  aberrant  thymic 
epithelial-thymocyte interaction. 
Summary 
Using monoclonal antibody 12/1-2 against a  19,000-dalton human T  cell leukemia 
virus (HTLV) protein (anti-p 19), previously demonstrated to be reactive with HTLV- 
infected human cells,  but  not in  numerous other uninfected cells,  we found a  reac- 
tive antigen to be expressed on the neuroendocrine component of human thymic epi- 
thelial cells but not on any other normal epithelial or neuroendocrine human tissues. 
Moreover,  this  reactive  antigen  is  acquired  on  neuroendocrine  thymic epithelium 
during thymic ontogeny--first appearing on fetal  thymic epithelial  cells  between  8 
and  15 wk gestation. While only a portion of thymic epithelial cells in the subcapsular 
cortical region of 15- and  24-wk fetal thymuses contained anti-pl9  + epithelial  cells, 
the entire subcapsular cortical region of newborn thymus epithelium  was anti-p 19  +. 
By  age  3  yr,  normal  subjects'  entire  subcapsular  cortical  and  medullary  thymic 
epithelium  was anti-pl9  +.  Using antibody against  HTLV core protein, p24,  and c- 
DNA probes for HTLV DNA, neither HTLV-specific p24 protein nor proviral DNA 
could be demonstrated in anti-p 19  + thymic epithelial tissue.  However, thymic epithe- 
lial  extracts,  disrupted  HTLV extracts,  as  well  as  purified  HTLV p19  antigen  all 
inhibited the binding of anti-pl9 antibody to thymic epithelium. Thus, anti-pl9 may 
recognize a  determinant on an HTLV-encoded 19,000-dalton structural protein that 
is shared by human thymic epithelium. Alternatively, anti-pl9 defines a host encoded 
protein that is selectively expressed by norman thymic epithelium, and is induced to 
be expressed in HTLV-infected malignant T  cells. 
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